OTC in general has a reputation for housing questionable companies, some with serious unethical practices. OTC has less conditions or requirement so their standards are lower.
However quite often it's pointed out how Eric is different than the others, and than at times like this it's said well this is the norm. So his WB different, or part of the norm.
The main point soon he will have to actually produce something to show that the potential outweighs the risk, and to stimulate interest in stock value.
I think he is already starting to drop the ball. Ok Eric we get it, GestureTek will take WB to the moon. What about this.
Have you received the assets yet? You said by end of June if memory serves me right. What about the new subsidiary company, did you incorporate one or is it GT Health. Who is the Action team.
Everyone talks about the wine. Yet no one knows what the affiliate revenue agreement is, or how it works. HADV showed a loss of -$130,000 or so, on its annual filing ending March 31st, 2022. How much can they afford to share on some royalty deal? Why doesn't he answer. Eric said the first run was already sold out. So what happened there? Do they have confirmed orders and deposits.?
The perfume was brought up like 15 years ago so sorry but that is distraction only at this point.
The potential might be there, on the tech, not sure Eric can deliver. Like you said we shall see soon enough, but might not be soon.
News 
Market Data 
Discover 
